Cargando…
Is there an association between liraglutide use and female breast cancer in a real-world setting?
BACKGROUND: Liraglutide is a human glucagon-like peptide-1 receptor agonist approved for treatment of adults with type 2 diabetes mellitus at a maximum dose of 1.8 mg/day (Victoza(®)) and more recently at 3.0 mg/day for weight management (Saxenda(®)). During the evaluation of liraglutide for approva...
Autores principales: | Funch, Donnie, Mortimer, Kathleen, Li, Ling, Norman, Heather, Major-Pedersen, Atheline, Olsen, Anne Helene, Kaltoft, Margit S, Dore, David D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254592/ https://www.ncbi.nlm.nih.gov/pubmed/30538516 http://dx.doi.org/10.2147/DMSO.S171503 |
Ejemplares similares
-
Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
por: Funch, Donnie, et al.
Publicado: (2019) -
Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
por: Funch, Donnie, et al.
Publicado: (2021) -
Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies
por: Funch, Donnie, et al.
Publicado: (2017) -
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
por: Funch, D, et al.
Publicado: (2014) -
A joint industry‐sponsored data monitoring committee model for observational, retrospective drug safety studies in the real‐world setting
por: Major‐Pedersen, Atheline, et al.
Publicado: (2020)